Tango Therapeutics' (TNGX) "Buy" Rating Reaffirmed at HC Wainwright

Tango Therapeutics (NASDAQ:TNGX - Get Free Report)'s stock had its "buy" rating reiterated by equities researchers at HC Wainwright in a research note issued on Monday,Benzinga reports. They currently have a $13.00 price objective on the stock. HC Wainwright also issued estimates for Tango Therapeutics' Q1 2025 earnings at ($0.35) EPS, Q2 2025 earnings at ($0.37) EPS, Q3 2025 earnings at ($0.39) EPS, Q4 2025 earnings at ($0.41) EPS, FY2025 earnings at ($1.52) EPS, Q1 2026 earnings at ($0.39) EPS, Q2 2026 earnings at ($0.37) EPS, Q3 2026 earnings at ($0.38) EPS, Q4 2026 earnings at ($0.40) EPS and FY2026 earnings at ($1.54) EPS.

Tango Therapeutics Stock Performance

Shares of NASDAQ:TNGX traded up $0.01 during midday trading on Monday, reaching $1.29. 467,141 shares of the company's stock were exchanged, compared to its average volume of 1,072,447. The company's 50 day simple moving average is $1.79 and its two-hundred day simple moving average is $3.29. Tango Therapeutics has a 12 month low of $1.11 and a 12 month high of $12.02. The firm has a market capitalization of $139.46 million, a PE ratio of -1.09 and a beta of 1.03.

Tango Therapeutics (NASDAQ:TNGX - Get Free Report) last announced its quarterly earnings results on Thursday, February 27th. The company reported ($0.35) EPS for the quarter, missing analysts' consensus estimates of ($0.32) by ($0.03). Tango Therapeutics had a negative return on equity of 49.64% and a negative net margin of 284.42%. The business had revenue of $4.12 million for the quarter, compared to the consensus estimate of $7.84 million. On average, research analysts anticipate that Tango Therapeutics will post -1.19 earnings per share for the current year.

Insider Activity

In other news, CEO Barbara Weber sold 9,778 shares of Tango Therapeutics stock in a transaction that occurred on Tuesday, February 4th. The shares were sold at an average price of $2.99, for a total value of $29,236.22. Following the completion of the transaction, the chief executive officer now owns 1,631,264 shares in the company, valued at approximately $4,877,479.36. The trade was a 0.60 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In the last quarter, insiders have sold 24,268 shares of company stock worth $72,561. Corporate insiders own 6.30% of the company's stock.

Hedge Funds Weigh In On Tango Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. State Street Corp raised its holdings in shares of Tango Therapeutics by 26.8% in the third quarter. State Street Corp now owns 2,318,208 shares of the company's stock valued at $17,850,000 after buying an additional 489,949 shares during the last quarter. XTX Topco Ltd increased its position in Tango Therapeutics by 340.1% in the 3rd quarter. XTX Topco Ltd now owns 44,191 shares of the company's stock valued at $340,000 after acquiring an additional 34,150 shares in the last quarter. Barclays PLC raised its stake in shares of Tango Therapeutics by 78.3% in the third quarter. Barclays PLC now owns 126,281 shares of the company's stock worth $972,000 after acquiring an additional 55,470 shares during the last quarter. Geode Capital Management LLC lifted its position in shares of Tango Therapeutics by 11.6% during the third quarter. Geode Capital Management LLC now owns 1,368,262 shares of the company's stock worth $10,538,000 after purchasing an additional 142,710 shares in the last quarter. Finally, Catalina Capital Group LLC bought a new stake in shares of Tango Therapeutics during the fourth quarter valued at approximately $82,000. Institutional investors and hedge funds own 78.99% of the company's stock.

About Tango Therapeutics

Tango Therapeutics, Inc, a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions.